Popular on s4story
- The Two Faces of Charles D. Braun: How the Novel, Posthumously Yours, Came to Life - 643
- Her Magic Mushroom Memoir Launches as a Binge-Worthy Novel-to-Podcast Experience - 633
- Conversations Media Group Expands with C.O.R.E., Mobilizes a Client Network to Amplify Voices - 582
- The Fantasy Novel of the Year: Wrath of the Spider King - 568
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience - 555
- Inspire, Excite, and Whet Your Appetite in "Matt's St. Louis Food Story" Available Now! - 543
- Nashville International Chopin Piano Competition Partners with Crimson Global Academy to Support Excellence in Education - 525
- Where the Miami Dolphins Stand After Week 1 - 511
- Which NFL Teams Can Rebound from Week 1? OddsTrader Breaks Down the Biggest Questions - 411
- Open Art Call | The Art of Artificial Intelligence | Copenhagen - 264
Similar on s4story
- DGiTK – Digital Technologies, LLC Announces Groundbreaking Partnership with Hyperscale Compute Partner to Revolutionize Data Sovereignty in the U.S
- SPOZZ, the Community-Owned Direct-to-Fan Music Ecosystem, adds "BEATS" — a Creator-to-Creator Marketplace
- Unprescribed™ Introduces the Focus, Mood & Mind System™
- $20 Target in Noble Capital Markets Report Supported by Live Stream of 1ST Global Super League Kerala Event from AI Powered Sports Leader: $SEGG
- Newest Mako Smartrobotics™ System Used for First Time in the State Of Illinois for Total Joint Replacement Surgery
- $20 Million Annualized Revenue Projected from 20+ Acquisitions and Scaling of Top Quality Dental Labs Across Florida: Standard Dental Labs $TUTH
- Lineus Medical Obtains CE Mark for Flagship Product SafeBreak Vascular
- David White DDS Advances Implant Dentistry with New Technology Acquisition
- $750 Million Market Projected to Reach $3.35 Billion; Huge Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression $NRXP
Vesica Health Granted PLA Billing Code for AssureMDx
S For Story/10673654
Enabling reimbursement and expanded patient access—Effective January 2026
IRVINE, Calif. - s4story -- VESICA HEALTH®, INC., a precision diagnostics company improving the early detection and management of bladder cancer, today announced that the American Medical Association (AMA) has granted a Proprietary Laboratory Analysis (PLA) billing code for its AssureMDx™ test. The new code, effective January 2026, represents a critical de-risking milestone in Vesica Health's path to commercialization, establishing a recognized billing pathway that will enable reimbursement and support adoption of AssureMDx across the U.S. healthcare system. This achievement positions Vesica Health to accelerate revenue generation and deliver meaningful near-term value creation for our shareholders, while at the same time expanding access for patients.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on S For Story
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on S For Story
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
"Securing a PLA code from the American Medical Association is a foundational milestone," said Christopher Thibodeau, Chief Executive Officer, Vesica Health. "It underscores the continued execution of our commercial strategy to expand access to AssureMDx, drive adoption across the healthcare system, and advance our mission to improve early detection and outcomes for patients, providers, and payers."
The AssureMDx PLA code (0613U) has been published in the AMA's Directory: https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes
By establishing a clear reimbursement pathway, this milestone validates Vesica Health's position with payers, enables provider adoption, expands patient access, and demonstrates the company's ongoing commitment to all stakeholders.
More on S For Story
- DGiTK – Digital Technologies, LLC Announces Groundbreaking Partnership with Hyperscale Compute Partner to Revolutionize Data Sovereignty in the U.S
- Delirious Comedy Club Expands to Two Rooms and Secures Google's #1 Rated Comedy Club in Las Vegas
- SPOZZ, the Community-Owned Direct-to-Fan Music Ecosystem, adds "BEATS" — a Creator-to-Creator Marketplace
- Reimagining the Literary Canon in the Age of Digital Suppression
- Digi 995 Expands the Digiverse with Free Coloring Pages and New Coloring App
About AssureMDx™
AssureMDx is a proprietary, noninvasive urine-based DNA test clinically validated to improve the early detection of bladder cancer. The assay integrates six genomic and epigenetic biomarkers—DNA methylation of TWIST1, OTX1, and ONECUT2, and somatic mutations in FGFR3, HRAS, and TERT—to stratify hematuria patients for expedited urologic evaluation while safely ruling out those at very low risk.
Vesica Health's genes and technology have been reported in more than 26 peer-reviewed publications involving over 8,500 patients across detection, prognostic, and predictive applications. This body of evidence includes three prospective clinical validation studies evaluating the final six-gene configuration of the AssureMDx assay for early detection. In the largest multicenter study (n=838; van Kessel et al., Journal of Urology, 2020), AssureMDx demonstrated an overall sensitivity of 96%, a negative predictive value greater than 99%, and an AUC of 0.96 for bladder cancer detection. Answering the clinical community's call for earlier, more accurate detection, AssureMDx achieved a combined sensitivity of 95.9% for Stage 0 (Ta and Tis/CIS) and Stage I disease—underpinning its unique ability to identify patients at increased risk for bladder cancer at its earliest and most treatable stages.
AssureMDx has been recognized in the AUA Clinical Guidelines as a validated urine-based genomic test for the evaluation of patients with intermediate-risk microscopic hematuria, further reinforcing its clinical utility within the standard of care.
More on S For Story
- A Futurists Dilemma of Breaking a Story of Phinge's Netverse, Patented App-less Technologies, Verified Rewards Platform and AI
- DAECO Painting Sets the Gold Standard for High-End Interior Painting Services in Denver, CO
- Chandra Donelson Headlines CDO Magazine's Chicago Leadership Summit
- BOOK RELEASE - Andrew Kooman's Gather for Advent
- Tanya Brockett Featured on Top-Ranked Podcast to Reveal the Hidden Wealth in Your Book
About Vesica Health®, Inc.
Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Hematuria—blood in the urine—affects more than 17 million U.S. adults annually, yet only 12% are referred for urologic evaluation, resulting in an estimated 20,000 missed bladder cancer diagnoses each year.
Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. In addition to its flagship assay, Vesica is advancing a pipeline that includes recurrence monitoring, prognostic, and predictive companion diagnostics.
Vesica Health is positioned to lead in the $6 billion bladder cancer diagnostics market, with a mission to improve survival and patient care through earlier detection, precision diagnostics, and expanded access to noninvasive solutions. Learn more at: www.vesicahealth.com.
For investment and partnership inquiries, or to learn more about AssureMDx, please contact Vesica Health Corporate Communications at: public.relations@vesicahealth.com
NOTE: The Vesica Health wordmarks and logos, including Vesica Health, and AssureMDx are trademarks or registered trademarks of Vesica Health, Inc. All other trademarks and service marks are the property of their respective owners.
Source: Vesica Health, Inc.
0 Comments
Latest on S For Story
- Announcing the "Utsunomiya Gyoza Festival 2025" to be held November 1 and 2 in Utsunomiya City, Tochigi Pref, Japan
- Lineus Medical Obtains CE Mark for Flagship Product SafeBreak Vascular
- Sine Nomine Associates: OpenAFS Google Summer of Code projects have been completed
- HuskyTail Digital Marketing Rings in Fall with Free SEO Audits for Local Businesses
- October Celebrates 15 Years of Ray Keating's Pastor Stephen Grant Thrillers and Mysteries
- Book Release - Gina School, It's Not What They Teach You; It's What You Learn by Gina Barreca
- David White DDS Advances Implant Dentistry with New Technology Acquisition
- Award-winning Children's Author Todd Cardin Releases New Book - Grampy, the Rhino and
- Final Countdown: The OpenSSL Conference 2025 Begins in One Week
- New Frontier Aerospace Appoints Industry Veteran Rich Pournelle as Director of Business Development
- AI's Urgent Energy Requirements Won't Be Solved By Trillions Of Dollars. Phinge's Patented App-Less Netverse Platform & Hardware Will Reduce This Need
- New Children's Story Book Spreads Holiday Cheer Through the Joy of Giving
- $750 Million Market Projected to Reach $3.35 Billion; Huge Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression $NRXP
- €6.4 Million in Contracts Across Multiple Countries; Smart City Developer; U.S. Expansion, and Announces Strategic Drone Tech Partnership; $AFFU
- CRYPTOCURRENCY: Lucrumia Exchange Platform Addresses Italian Traders' Growing Demand for Secure Digital Asset Trading
- NIUFO Launches Secure Trading Platform for Italian Market Seeking Stability After 20% User Decline
- World Premiere English translation of Rilke's Testament
- OrderDomains.com Empowers Businesses with Premium Domains and Flexible Financing
- Cryptocurrency Trading: AHRFD Enters German Market with Institutional-Grade Infrastructure
- TSWHZC Launches Automated Copy Trading Platform for Brazil's 28 Million Crypto Users